Breo Ellipta® Inhalation Powder for Asthma and COPD

What Breo Ellipta® Is and How It Works

Breo Ellipta® is a once-daily combination inhaler for long-term control of asthma and chronic obstructive pulmonary disease (COPD). It contains fluticasone furoate, an inhaled corticosteroid that reduces airway inflammation, and vilanterol, a long-acting beta2-agonist (LABA) that relaxes airway muscles to improve airflow. The active ingredients are often shortened to fluticasone/vilanterol or fluticasone vilanterol.

YouDrugstore is a licensed Canadian pharmacy headquartered in Manitoba, and all prescriptions are reviewed by licensed pharmacists before dispensing.

Breo Ellipta® is a maintenance therapy, not a rescue inhaler. It helps prevent symptoms such as wheeze, chest tightness, and shortness of breath, and reduces exacerbations. The Ellipta dry powder device delivers a measured dose with one inhalation, once a day at the same time. Common strengths are 100/25 mcg and 200/25 mcg. The 100/25 strength is often used for COPD, while asthma treatment may start at 100/25 and increase to 200/25 if needed. Do not use it for sudden breathing problems; keep a quick-relief inhaler on hand.

We work with licensed, vetted partner pharmacies internationally to supply authentic brand inhalers, broad selection, and affordable pricing.

Dosage and Usage

• Usual dosing: one inhalation once daily. Take at the same time each day.
• Asthma: start at 100/25 mcg. Increase to 200/25 mcg if control is inadequate.
• COPD: 100/25 mcg once daily is typical. Higher strength is not routinely used for COPD.
• Not for acute bronchospasm. Use a rescue inhaler for sudden symptoms.
• Rinse mouth with water and spit after each dose to lower the risk of thrush.
• Do not exceed one dose in 24 hours.

• Ellipta device steps: open the cover fully until a click loads the dose.
• Exhale away from the mouthpiece. Do not exhale into the device.
• Seal lips around the mouthpiece. Inhale steadily and deeply.
• Hold breath for about 3–4 seconds, then breathe out slowly.
• Close the cover. The dose counter will decrease by one.
• Do not shake, block the air vents, or wash the device.

• Missed dose: if a dose is missed, take the next dose at the regular time. Do not double up.
• Overdose signs may include tremor, rapid heartbeat, or chest pain. Seek medical help.

• Storage: keep sealed in the foil tray until first use. Store at 20–25°C (68–77°F).
• Use within 6 weeks after opening the tray or when the counter reads 0, whichever comes first.
• Keep dry. Avoid heat, humidity, and direct sunlight. Do not refrigerate or freeze.
• Travel: keep the inhaler in your carry-on. Protect from crushing. Bring your prescription.
• Keep out of reach of children and pets.

Benefits and Savings

Breo Ellipta® offers once-daily convenience for asthma and COPD control. The combination of an inhaled corticosteroid and a LABA improves lung function, reduces day and night symptoms, and lowers the risk of exacerbations. Many people find the Ellipta device simple to use, with a built-in dose counter and consistent dose delivery.

Buying from Canada can provide significant savings. Typical customers see 60–80% lower costs versus usual US retail prices. Breo Ellipta cost differs by strength and package size, and multi-month supplies can reduce the per-month price. Compare Breo Ellipta price by strength (100/25 vs 200/25) to choose the most economical option prescribed.

For extra savings, see our breo ellipta coupon on the promotions page.

Side Effects and Safety

• Headache
• Throat irritation or hoarseness
• Oral thrush (candidiasis)
• Cough
• Upper respiratory tract infection
• Nasopharyngitis or sinusitis
• Back pain or joint pain
• Rapid heartbeat, palpitations, or tremor
• Nausea
• Bronchitis

Serious but less common risks include pneumonia (seen more in COPD patients), paradoxical bronchospasm, allergic reactions including hives or swelling, adrenal suppression, weakened immunity, reduced bone mineral density, glaucoma, cataracts, and changes in heart rhythm. The Ellipta device contains lactose; avoid use in severe milk protein allergy. LABAs should not be used alone in asthma; Breo Ellipta® includes an ICS to mitigate that risk. Seek urgent care for severe breathing trouble, chest pain, or facial swelling.

Hypoglycemia warnings apply to insulin or sulfonylurea combinations; this inhaler does not increase low blood sugar risk.

Onset Time

Bronchodilation from the vilanterol component can begin within minutes, and some symptom relief may be noticed after the first dose. Anti-inflammatory benefits from fluticasone build over time. Asthma control often improves within 1–2 weeks, with maximum benefit by about 4–6 weeks. In COPD, improvement in lung function and fewer exacerbations are typically seen over several weeks to months with regular daily use.

Compare With Alternatives

Symbicort (budesonide/formoterol) is another ICS/LABA inhaler. It is usually taken as two puffs twice daily, and in some asthma plans it can be used as both maintenance and reliever therapy. People who prefer once-daily dosing may favor Breo Ellipta®, while those who want adjustable puffs may prefer a metered-dose inhaler.

Advair or its generic equivalents (fluticasone propionate/salmeterol) also combine an ICS with a LABA. Diskus and HFA formats differ in device type and dosing frequency. Patients well controlled on twice-daily regimens may remain on them, while others may switch to once-daily fluticasone furoate/vilanterol based on prescriber guidance and insurance or price considerations.

A long-acting muscarinic antagonist (LAMA) may be used instead of, or added to, an ICS/LABA. Examples include tiotropium as a soft-mist device like Spiriva® Respimat Inhaler. For quick relief, a short-acting beta-agonist such as salbutamol is commonly used; Diskus users may prefer Ventolin® Diskus as a rescue option. Therapy choice depends on diagnosis, severity, device preference, and prior response.

Combination Therapy

• ICS/LABA plus SABA: keep a short-acting beta-agonist rescue inhaler available for sudden symptoms.
• Triple therapy for COPD: add a LAMA (for example, tiotropium) to ICS/LABA when exacerbations persist.
• Asthma step-up: consider adding a LAMA or leukotriene receptor antagonist if control is inadequate.
• Oral corticosteroid bursts may be used short-term for exacerbations, then tapered per prescriber plan.
• Space each inhaler’s dose to avoid confusion and ensure correct technique with every device.

Patient Suitability and Cost-Saving Tips

Breo Ellipta® is used for maintenance treatment of asthma in adults and children 5 years and older, and for maintenance treatment of COPD in adults. It is not appropriate for acute bronchospasm or status asthmaticus. People with severe milk protein allergy, uncontrolled cardiovascular disease, or certain arrhythmias may need alternative options. Those with glaucoma, cataracts, osteoporosis, or chronic infections require monitoring when using inhaled corticosteroids.

Device technique matters. If symptoms continue, improper inhalation or poor adherence may be the cause. A prescriber or pharmacist can assess technique and adjust dose or therapy if needed. For asthma, the 100/25 and 200/25 strengths offer flexibility; for COPD, 100/25 is standard. The generic name for Breo is fluticasone furoate/vilanterol; at this time, there is no interchangeable generic Breo Ellipta in Canada or the US.

To reduce costs, consider a 3‑month supply to lower the per-month price and decrease shipping fees. Turn on reorder reminders so refills are not missed. Compare Breo Ellipta cost by strength and pack size. Bulk promotions may be available during select periods. We ship with prompt, express service to the US once your prescription is verified.

Authoritative Sources

For detailed prescribing information, see these references:

FDA Prescribing Information for Breo Ellipta (fluticasone furoate/vilanterol)

Health Canada Drug Product Database: Breo Ellipta

GSK Product Information for Breo Ellipta

Order Breo Ellipta® from Youdrugstore: add to cart, upload your prescription, and we ship with prompt, express, cold-chain handling.

This page is educational and does not replace advice from your healthcare professional.